1. Generics Bulletin
  2. >>Products
  3. >>Value Added Medicines

The Path Ahead: Medicines For Europe Head Highlights Opportunities And Risks

Examining The Future Landscape For Generics, Biosimilars And Value Added Medicines

 
• By Dave Wallace

In the third and final part of an exclusive three-part interview with Generics Bulletin, Medicines for Europe director general Adrian van den Hoven looks to the opportunities ahead for value added medicines and biosimilars in Europe, as well as the potential solutions to the pressures facing small-molecule generics.

Adrian van den Hoven at Medicines for Europe's 18th Biosimilar Medicines Conference
Adrian van den Hoven looks to the future for off-patent medicines in Europe • Source: Medicines for Europe

With Medicines for Europe’s director general Adrian van den Hoven having spoken to Generics Bulletin about his early days with the association as well as reflecting on achievements and challenges over the past ten years (see sidebars), the final part of his exclusive three-part interview looks ahead to the opportunities that are on the horizon for generics, biosimilars and value added medicines in Europe.

First of all, van den Hoven was asked about the potential for value added medicines to gain ground in future, especially given recent EU legislative efforts to recognise the value of repurposing with a proposed four-year period of data exclusivity protection for new indications

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Value Added Medicines

BGMA Becomes Medicines UK

 
• By Dave Wallace

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.

Iconovo Slims Down As It Focuses On Commercialization

 
• By Dave Wallace

As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.

How To Make The Most Of Your GGB Awards Entries

 
• By Dave Wallace

With the Global Generics & Biosimilars Awards 2025 taking place in Frankfurt this October, we bring you five key pieces of guidance to help ensure that your entries stand out from the competition.

Teva Shares Encouraging Patient Survey Data For Long-Acting Olanzapine

 
• By Adam Zamecnik

Doubling down on previously shared data from the firm’s STELARIS trial, Teva has reported further findings from a survey featuring subjects and professionals involved in the Phase III study for its proposed long-acting olanzapine injectable.

More from Products

Trump Order On Domestic Manufacturing Wins Plaudits From Industry

 
• By Dave Wallace

An executive order from US president Donald Trump aimed at incentivizing domestic manufacturing of critical medicines has been welcomed by the US Association for Accessible Medicines.

Teva And Alvotech Celebrate Interchangeability For US Ustekinumab

 
• By Dave Wallace

The market for biosimilar rivals to Stelara continues to be hotly contested in the US, with partners Teva and Alvotech claiming a boost from an interchangeability designation at the same time as Biocon Biologics highlighted fresh market access agreements.

Amgen Biosimilars Continue Surge Ahead Of Imminent Denosumab Competition

 
• By Dean Rudge

Thanks to its efficient development pipeline, sales of Amgen’s biosimilars neared $750m for the first three months of the year, offering some comfort as the firm gears up for the loss of exclusivity for its denosumab franchise.